AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20506254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 20506254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses combined)
Number of subjects: 264
Study 18160461 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 weeks
Number of subjects: 121
Study 17063637 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR) tablets (30 mg)
Number of subjects: 0
Study 17063637 — intervention group
Group type: COMPARATOR
Intervention: Commercial gliclazide standard preparation (30 mg)
Number of subjects: 0
Study 14628980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg
Number of subjects: 310
Study 14628980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 10699688 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus best supportive care (BSC)
Number of subjects: 207
Study 10699688 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 207
Study 9243044 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg/d)
Number of subjects: 29
Study 9243044 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg/d)
Number of subjects: 29
Study 9243044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (1,500 mg/d)
Number of subjects: 29
Study 8478235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia treatment (60 min, 1 or 2 times per week during irradiation)
Number of subjects: 111
Study 2945109 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of bed rest (Group I)
Number of subjects: 203
Study 2945109 — intervention group
Group type: COMPARATOR
Intervention: 7 days of bed rest (Group II)
Number of subjects: 203
Study 31564236 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient physical therapy intervention including a 1-hour initial assessment and individualized treatment plans
Number of subjects: 50
Study 31564236 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment 10-meter gait speed measurement
Number of subjects: 50
Study 29111115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg/day)
Number of subjects: 126
Study 29111115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 24504832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clubhouse
Number of subjects: 167
Study 24504832 — intervention group
Group type: COMPARATOR
Intervention: PACT
Number of subjects: 167
Study 24662192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10ug bd for 12 months
Number of subjects: 44
Study 24662192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exenatide)
Number of subjects: 44
Study 22441448 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 1 ml betamethasone and 1 ml prilocaine on the lateral epicondyle at the point of maximum tenderness.
Number of subjects: 80
Study 22441448 — intervention group
Group type: COMPARATOR
Intervention: Injection of the same drug mixture with needle tip redirected and reinserted down the bone approximately 30 to 40 times without emerging from the skin, creating a hematoma.
Number of subjects: 80
Study 19933822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome treatment (normalization of corticosteroid excess)
Number of subjects: 15
Study 19933822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for Cushing's syndrome)
Number of subjects: 15
Study 16904718 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ 50 mg/kg
Number of subjects: 729
Study 16904718 — intervention group
Group type: COMPARATOR
Intervention: CQ 25 mg/kg
Number of subjects: 729
Study 16904718 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ 15 mg/kg
Number of subjects: 729
Study 16904718 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ 30 mg/kg
Number of subjects: 729
Study 16168215 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (group B)
Number of subjects: 60
Study 16168215 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (group A)
Number of subjects: 60
Study 11787985 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg zinc as gluconate, orally, for 12 weeks)
Number of subjects: 20
Study 11787985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 9254876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 21
Study 8495450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 18
Study 8495450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8495450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation attack
Number of subjects: 18
Study 3505872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic training (8 hours)
Number of subjects: 76
Study 3505872 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 76
Study 31987566 — intervention group
Group type: EXPERIMENTAL
Intervention: Geotherapy combined with kinesiotherapy (GK)
Number of subjects: 48
Study 31987566 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (K)
Number of subjects: 48
Study 28945160 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-delivered behaviour activation treatment (BAT)
Number of subjects: 90
Study 28945160 — intervention group
Group type: COMPARATOR
Intervention: Same-room behaviour activation treatment (BAT)
Number of subjects: 90
Study 27059816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg/week
Number of subjects: 409
Study 27059816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg/week
Number of subjects: 409
Study 27059816 — intervention group
Group type: COMPARATOR
Intervention: Metformin ≥1500 mg/day
Number of subjects: 409
Study 24063860 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib plus interleukin-2 (IL-2) 400 mg twice daily plus subcutaneous IL-2 4.5 million international units (MIU) five times per week for 6 weeks every 8 weeks (arm A)
Number of subjects: 128
Study 24063860 — intervention group
Group type: COMPARATOR
Intervention: sorafenib alone (arm B)
Number of subjects: 128
Study 21463474 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy 40 mg whole (fed)
Number of subjects: 0
Study 21463474 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy 40 mg chewed (fed)
Number of subjects: 0
Study 21463474 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone ER 40 mg (crushed, fasted)
Number of subjects: 0
Study 21463474 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR 40 mg (crushed, fasted)
Number of subjects: 0
Study 21463474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21463474 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone ER 40 mg (whole and chewed)
Number of subjects: 0
Study 18375416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 16332
Study 18375416 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16332
Study 16434523 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigated total knee arthroplasty
Number of subjects: 24
Study 16434523 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional surgical technique using intramedullary alignment guides
Number of subjects: 24
Study 12927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg daily)
Number of subjects: 49
Study 12927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg daily)
Number of subjects: 49
Study 12927657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10694099 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis test for SM+ patients
Number of subjects: 0
Study 10694099 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis test for EPT patients
Number of subjects: 0
Study 10694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of SM+ patients
Number of subjects: 0
Study 10694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of confirmed EPT patients
Number of subjects: 0
Study 10694099 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT Tuberculosis assay
Number of subjects: 0
Study 9301442 — intervention group
Group type: EXPERIMENTAL
Intervention: B-CHOP-M (bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate)
Number of subjects: 325
Study 9301442 — intervention group
Group type: COMPARATOR
Intervention: PEEC-M (methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate) alternating with B-CHOP-M
Number of subjects: 325
Study 8359098 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 12
Study 8359098 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 12
Study 3675008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenytoin
Number of subjects: 60
Study 3675008 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular gold
Number of subjects: 60
Study 29290068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% minoxidil cream applied twice daily for 2 weeks
Number of subjects: 88
Study 29290068 — intervention group
Group type: COMPARATOR
Intervention: 2% diltiazem cream applied twice daily for 2 weeks
Number of subjects: 88
Study 26996811 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff and scapular strengthening exercises for 4 weeks
Number of subjects: 36
Study 26996811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 36
Study 24239790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 59
Study 24239790 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 59
Study 24239790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cathodal tDCS + VR)
Number of subjects: 59
Study 24239790 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 23725851 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus panitumumab (IrPan)
Number of subjects: 460
Study 23725851 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 460
Study 19946216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone recall system managed by pediatricians
Number of subjects: 205
Study 19946216 — intervention group
Group type: COMPARATOR
Intervention: Anonymous recall system
Number of subjects: 205
Study 19040589 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1235
Study 19040589 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1235
Study 19040589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1235
Study 21974764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 10-20 mg
Number of subjects: 261
Study 21974764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 40-80 mg
Number of subjects: 261
Study 21974764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80-160 mg
Number of subjects: 261
Study 21974764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (after re-randomization)
Number of subjects: 261
Study 21974764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after re-randomization)
Number of subjects: 261
Study 15668554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Number of subjects: 11
Study 15668554 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest physical treatments
Number of subjects: 11
Study 11867177 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (28-day course)
Number of subjects: 25
Study 11867177 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear neutrophils (PMN)
Number of subjects: 25
Study 11867177 — intervention group
Group type: COMPARATOR
Intervention: AH patients
Number of subjects: 25
Study 11867177 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated blood PMN from AH patients
Number of subjects: 25
Study 11867177 — intervention group
Group type: EXPERIMENTAL
Intervention: Formyl-Methionyl-Leucyl-Phenylalanine-induced PMN
Number of subjects: 25
Study 9517989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg three times/day
Number of subjects: 994
Study 9517989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 9517989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg three times/day (at protocol amendment)
Number of subjects: 994
Study 9517989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (at protocol amendment)
Number of subjects: 994
Study 9517989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) for patients taking didanosine (ddI)
Number of subjects: 994
Study 9517989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) for patients not taking didanosine (ddI)
Number of subjects: 994
Study 8044950 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic counterpulsation
Number of subjects: 182
Study 8044950 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 182
Study 3261547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection in the antecubital fossa
Number of subjects: 0
Study 3261547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol mixed with lignocaine
Number of subjects: 0
Study 3261547 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowing the speed of injection
Number of subjects: 0
Study 31035808 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived cancer-related benefits of quitting smoking
Number of subjects: 303
Study 29323616 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced bipolar instruments (LigaSure)
Number of subjects: 68
Study 29323616 — intervention group
Group type: COMPARATOR
Intervention: Conventional bipolar instruments (Robi forceps)
Number of subjects: 68
Study 26445384 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm vertical compaction (WVC)
Number of subjects: 16
Study 26445384 — intervention group
Group type: COMPARATOR
Intervention: Single match tapered size cone technique (SMTSC)
Number of subjects: 16
Study 25719444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-ketamine (group SK)
Number of subjects: 100
Study 25719444 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-saline (group SS)
Number of subjects: 100
Study 24389403 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of red wine
Number of subjects: 0
Study 24389403 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of vodka
Number of subjects: 0
Study 24389403 — intervention group
Group type: COMPARATOR
Intervention: Congeners of red wine
Number of subjects: 0
Study 24389403 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 0
Study 20574104 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen peripherally inserted central catheter (PICC)
Number of subjects: 50
Study 18675399 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress (prior to receiving methadone dose)
Number of subjects: 41
Study 18675399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress (immediately following methadone dose)
Number of subjects: 41
Study 17186094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose streptokinase (500,000 to 750,000 U)
Number of subjects: 166
Study 17186094 — intervention group
Group type: COMPARATOR
Intervention: Classical therapy (1.5 million U)
Number of subjects: 166
Study 14595471 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding challenge test
Number of subjects: 77
Study 10788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-based teacher-delivered sex education programme
Number of subjects: 0
Study 10788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger video sessions and role-play techniques for sexual negotiation
Number of subjects: 0
Study 10788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-sex student groups for reflection on gendered construction of sexuality
Number of subjects: 0
Study 10788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials tailored to recipients' circumstances
Number of subjects: 0
Study 8891642 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 40
Study 8891642 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychiatric subjects
Number of subjects: 40
Study 8891642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 1680135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of zidovudine
Number of subjects: 25
Study 1680135 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of zidovudine
Number of subjects: 25
Study 1680135 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 25
Study 6134543 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 3 mg
Number of subjects: 8
Study 6134543 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 15 mg
Number of subjects: 8
Study 6134543 — intervention group
Group type: COMPARATOR
Intervention: diazepam 5 mg
Number of subjects: 8
Study 6134543 — intervention group
Group type: COMPARATOR
Intervention: lorazepam 1 mg
Number of subjects: 8
Study 6134543 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 30531464 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdoses of recombinant human erythropoietin (rHuEpo) (20‐40 IUkg) administered twice per week for 7 weeks
Number of subjects: 14
Study 30531464 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice per week for 7 weeks
Number of subjects: 14
Study 27534639 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation during pregnancy
Number of subjects: 1300
Study 27534639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 24449229 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth personalized risk assessment and communication intervention
Number of subjects: 481
Study 24449229 — intervention group
Group type: COMPARATOR
Intervention: Mailed educational brochure
Number of subjects: 481
Study 22420466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane sedation
Number of subjects: 100
Study 22420466 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 100
Study 20831358 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste with no post-brushing water rinsing
Number of subjects: 20
Study 20831358 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride toothpaste with three sessions of post-brushing water rinsing
Number of subjects: 20
Study 18053628 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 21 days
Number of subjects: 20
Study 18053628 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 21 days
Number of subjects: 20
Study 18053628 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil treatment
Number of subjects: 20
Study 18053628 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 15945001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 35
Study 15945001 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/Timolol fixed combination (DTFC) 0.5%/2%
Number of subjects: 35
Study 15552533 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy with antihypertensive drugs (E1)
Number of subjects: 110
Study 15552533 — intervention group
Group type: COMPARATOR
Intervention: Single diet therapy (E2)
Number of subjects: 110
Study 11208882 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA radiation
Number of subjects: 50
Study 11208882 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB radiation
Number of subjects: 50
Study 11208882 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (2 Gy)
Number of subjects: 50
Study 11208882 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (54 Gy)
Number of subjects: 50
Study 11208882 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and p21 correlation
Number of subjects: 50
Study 11208882 — intervention group
Group type: COMPARATOR
Intervention: Erythema (radiation dermatitis)
Number of subjects: 50
Study 9064058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 3 days
Number of subjects: 421
Study 9064058 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 800 mg twice daily for 10 days
Number of subjects: 421
Study 8341188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose salbutamol (2.5 mg)
Number of subjects: 99
Study 8341188 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable dose salbutamol (0.1 mg/kg bodyweight)
Number of subjects: 99
Study 8341188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations of salbutamol
Number of subjects: 99
Study 3525883 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 (1,500 mg/day, 750 mg after breakfast and supper for 14 days)
Number of subjects: 195
Study 3525883 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL) (1,500 mg/day, 500 mg after every meal for 14 days)
Number of subjects: 195
Study 3525883 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMPC) (2,000 mg/day, 500 mg after every meal and at bedtime for 14 days)
Number of subjects: 195
Study 31236731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacks
Number of subjects: 48
Study 31236731 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 48
Study 28849779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg over 40 min)
Number of subjects: 18
Study 28849779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 18
Study 28849779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 18
Study 28849779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26414893 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided online CBT-I
Number of subjects: 90
Study 26414893 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual face-to-face CBT-I
Number of subjects: 90